https://doi.org/10.55788/d3ebb775
The study included adults with ongoing laryngeal symptoms who underwent LPR evaluation, using either an upper gastrointestinal endoscopy or ambulatory reflux monitoring [1]. Patients were classified as LPR-positive or LPR-negative based on the evidence of gastroesophageal reflux disease.
A total of 304 patients were included, of whom 130 were LPR-positive and 174 LPR-negative. LPR-positive patients were predominantly older males with higher body mass index, presenting with regurgitation and cough. Conversely, LPR-negative patients often experienced globus sensation.
The optimal predictive model for the 'COugH RefluX Score' combines 6 parameters: the presence of cough, overweight/obesity status, globus sensation, hiatal hernia, regurgitation, and male sex. Globus emerged as a negative predictor (OR 0.51; 95% CI 0.30–0.86; P=0.01).
Patients' scores fell into 3 categories: ≤2.5 (low LPR likelihood), between 3 and 4.5 (inconclusive), and ≥5 (high LPR likelihood). The model demonstrated an 82% sensitivity in predicting LPR (95% CI 0.75–0.88) in scores over 2.5 and 84% specificity for scores over 5 (95% CI 0.77-0.89).
The model was also examined without the hiatal hernia parameter, as this is not always readily available. The model’s reliability was confirmed even without this variable. The study also involved salivary pepsin tests in a subgroup of patients. The inclusion of salivary pepsin tests increased the model’s overall sensitivity to 87%, with 48% specificity.
The study’s limitations include its single-centre scope and the absence of therapeutic outcome evaluation. Nonetheless, the 'COuGH RefluX Score' successfully stratifies LPR likelihood, prompting further testing when necessary. Current efforts focus on the model's external validation across 3 US and 1 international site. Preliminary results appear promising, with plans for a prospective study to validate the score against treatment outcomes.
- Krause A, et al. Novel clinical risk prediction score for laryngopharyngeal reflux. Lecture 936, DDW 2023, 6–9 May, Chicago, IL, USA.
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« Excellent results for C21 in idiopathic pulmonary fibrosis Next Article
Linaprazan glurate in the treatment of erosive oesophagitis »
« Excellent results for C21 in idiopathic pulmonary fibrosis Next Article
Linaprazan glurate in the treatment of erosive oesophagitis »
Table of Contents: DDW 2023
Featured articles
EVOLVE Expansion study: vedolizumab and ustekinumab as first-line biologic treatments for Crohn’s disease
PIPAC technique shows promise for unresectable colorectal peritoneal metastases
Upper GI Disorders: Hot Topics
Dupilumab improves eosinophilic oesophagitis outcomes, regardless of history of oesophageal dilation
Inflammatory Bowel Disease: Novel Developments
EVOLVE Expansion study: vedolizumab and ustekinumab as first-line biologic treatments for Crohn’s disease
Environmental and dietary factors can amplify paediatric IBD risk
Ulcerative colitis: bowel urgency remission associated with improvement in fatigue
Crohn’s disease: Upadacitinib improves endoscopic outcomes in participants with or without previous biologic failure
Microbiota in GI Diseases
Durability of SER-109 clinical response in patients with recurrent Clostridioides difficile infection
IBS management: the complex role of dietary fibres
Daily and seasonal fluctuations in the gut microbiome
Spotlight on Colorectal Cancer
Colorectal cancer: Aspirin and NSAIDs could reduce the risk of early-onset adenomas
PIPAC technique shows promise for unresectable colorectal peritoneal metastases
What is New in Hepatology?
Terlipressin shows promise for participants with hepatorenal syndrome and concomitant alcoholic hepatitis
Related Articles
January 29, 2021
Cigarette smoke tied to colorectal neoplasia in IBD patients
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy